Skip to main content
. Author manuscript; available in PMC: 2013 Jul 20.
Published in final edited form as: J Control Release. 2012 Jan 21;161(2):338–350. doi: 10.1016/j.jconrel.2012.01.018

Figure 4.

Figure 4

Optical micrographs of DEBs. (a) Unloaded 500–700 μm DEB; (b) Doxorubicin (18.2 mg/mL) loaded 500–700 μm DEB; (c) Mitoxantrone (19.8 mg/mL) loaded 500–700 μm DEB. Note the effect of mono or divalent drug binding on bead size and the color imparted by the drug. (d) Unloaded DEB (70–150 μm); (e) Doxorubicin (37.5 mg/mL) loaded DEB (70–150 μm); (f) Irinotecan (50 mg/mL) loaded DEB (70–150 μm). Note that these DEBs (d, e and f) are much smaller than that used to conduct the early Phase I/II clinical studies with DEB (b).